Search Results - "Bretti, S"

Multimodal management of stages III–IVa malignant thymoma by Bretti, S, Berruti, A, Loddo, C, Sperone, P, Casadio, C, Tessa, M, Ardissone, F, Gorzegno, G, Sacco, M, Manzin, E, Borasio, P, Sannazzari, G.L, Maggi, G, Dogliotti, L

“…Purpose: The optimal therapy for locally advanced malignant thymoma is controversial. We review our experience with a multimodal approach in 63 consecutive…”
Get full text

Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer by DI RENZO, M. F, OLIVERO, M, PLEBANI, M, GESPACH, C, COMOGLIO, P. M, GIACOMINI, A, PORTE, H, CHASTRE, E, MIROSSAY, L, NORDLINGER, B, BRETTI, S, BOTTARDI, S, GIORDANO, S

“…The c-met oncogene encodes the receptor for hepatocyte growth factor/scatter factor, a potent mitogen for epithelial cells that also promotes cell motility and…”
Get full text

Expression of the Met/HGF receptor in normal and neoplastic human tissues by Di Renzo, M F, Narsimhan, R P, Olivero, M, Bretti, S, Giordano, S, Medico, E, Gaglia, P, Zara, P, Comoglio, P M

“…The MET oncogene encodes a transmembrane tyrosine kinase receptor. Recently, hepatocyte growth factor (HGF), a potent growth factor for hepatocytes involved in…”
Get more information

Weekly cisplatin plus capecitabine in metastatic breast cancer patients heavily pretreated with both anthracycline and taxanes by Donadio, M, Ardine, M, Berruti, A, Beano, A, Bottini, A, Mistrangelo, M, Bonardi, S, Castiglione, F, Generali, D, Polimeni, M A, Bretti, S, Alabiso, O, Bertetto, O

“…Treating patients with anthracycline- and taxane-pretreated metastatic breast cancer is challenging. This study evaluated the activity and safety of a…”
Get more information

Gemcitabine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a phase II study by Bretti, S, Manzin, E, Loddo, C, Berruti, A, Bombaci, S, Vellani, G, Celano, A

“…Lung cancer is the leading cause of cancer death in men worldwide; most cases are not suitable for radical surgery at diagnosis and palliative treatment…”
Get more information

Low dose carboplatin (AUC 4.5) combined with vinorelbine in the treatment of advanced non-small cell lung cancer: a single institution phase II study by Bretti, S, Manzin, E, Celano, A, Ritorto, G, Loddo, C, Berruti, A

“…Platinum compounds and vinorelbine (VNB) are active in the treatment of non-small cell lung cancer (NSCLC), but moderate toxicity has been reported. The aims…”
Get more information

Interleukin-3 In Vivo: Kinetic of Response of Target Cells by Aglietta, M., Sanavio, F., Stacchini, A., Morelli, S., Fubini, L., Severino, A., Pasquino, P., Volta, C., Bretti, S., Tafuto, S., Zola, P., Sismondi, P., Sklenar, I., Piacibello, W., Bussolino, F., Gavosto, F.

“…Human recombinant interleukin-3 (IL-3; Sandoz AG, Basel, Switzerland) was administered for 7 days to patients with neoplastic disease and normal hematopoiesis…”
Get full text

Circulating microRNAs (miRNAs): Biomarkers for Lung Cancer by Adami, F., Porcile, G., Ridolfi, R., Labianca, R., Palazzo, S., Bretti, S., Gentilini, P., Carbonardi, F., Oliani, C., Aitini, E.

Get full text

“Green oncology”: a new paradigm for medical oncology by Porcile, G., Aitini, E., Bretti, S., Crispino, S., Oliani, C., Romizi, R., Cova, D., Savia, F., Clerico, M., Palazzo, S., Labianca, R., Adami, F.

Get full text

Multicenter Phase II trial of intermediate dose cisplatin and vinorelbine in inoperable non-small cell lung cancer patients by Bretti, S., Berruti, A., Gorzegno, G., La Ciura, P., Pazè, E., Celano, A., Grecchi, G., Perroni, D., Bumma, C., Dogliotti, L.

“…Vinorelbine (VNB) and cisplatin (CDDP) combination regimen was found active in the treatment of advanced non-small cell lung cancer (NSCLC) patients, but…”
Get full text

Palmar-plantar erythrodysestasia syndrome associated with 5-fluorouracil treatment by Comandone, A, Bretti, S, La Grotta, G, Manzoni, S, Bonardi, G, Berardo, R, Bumma, C

“…Palmar-Plantar Erythrodysestasia Syndrome (PPES) or Hand-Foot Syndrome (H&F S) is an underestimated adverse reaction to chemotherapeutic agents, mainly related…”
Get more information

Effects of Vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung Cancer

Get full text

Phase II study of the activity and tolerability of a combined regimen of high-dose epirubicin and cisplatin in stage IIIb and IV non-small cell lung cancer by Clerici, M, De Marinis, F, Piazza, E, Frontini, L, Tucci, E, Barni, S, Bretti, S, Luporini, G, Intini, C

“…To explore the feasibility and activity of a combined regimen of high-dose epirubicin and cisplatin as an alternative to current treatments for non-small cell…”
Get more information

Non small cell lung cancer treatment with vinorelbine monochemotherapy: a phase II study by Clerici, M, Bretti, S, Celano, A, Panvini, D, Comandone, A, Casadio, C, Luporini, G, Bumma, C

“…Non small cell lung cancer is one of the leading causes of death in the industrial countries and some 70% of patients have non surgically eradicable disease…”
Get more information

An open phase I study to assess the biological effects of a continuous intravenous infusion of interleukin-3 followed by granulocyte macrophage-colony stimulating factor by Bretti, S., Gilleece, M.H., Kamthan, A., Fitzsimmons, L., Hicks, F., Rowlands, M., Bishop, P., Picardo, A.-M., Dexter, T.M., Scarffe, J.H.

“…To assess any synergistic stimulatory effect in vivo of Interleukin 3 (IL-3) and Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) upon white cell and…”
Get full text

Stability of ifosfamide in solutions for multiday infusion by external pump by Leone, L, Comandone, A, Oliva, C, Bussi, P, Goffredo, F, Bretti, S, Bumma, C

“…The stability of ifosfamide in Ringer lactate buffer solution either alone or mixed with mesna at 37 degrees C for a 7-day period was analyzed by HPLC. This…”
Get more information

Preoperative concurrent radiation therapy and cisplatinum continuous infusion in IIIa (N2) non small cell lung cancer. A pilot study by Maggi, G, Casadio, C, Cianci, R, Oliaro, A, Molinatti, M, Bretti, S, Clerico, M, Boidi-Trotti, A, Rovea, P

“…From April 1991 to September 1993, 18 patients affected by a presumed operable IIIa (N2) non small cell lung cancer (NSCLC) with histologically confirmed bulky…”
Get more information

Non small cell lung cancer treatment with carboplatin and vindesine: a phase II study by Bretti, S, Bonardi, G M, Celano, A, Comandone, A, Casadio, C, Marchisio, U, Forconi, G, Manzoni, S, Bumma, C

“…A phase II trial aiming to verify the effectiveness of a regimen including carboplatin and vindesine was performed. From November 1989 to September 1990,…”
Get more information

Monoclonal antibodies against murine IFN-gamma abrogate in vivo tumor immunity against RSV-induced murine sarcomas by Prat, M, Bretti, S, Amedeo, M, Landolfo, S, Comoglio, PM

“…Previous work has shown that immunization of syngeneic mice with v-src-induced sarcomas gives rise to specific protection against a lethal dose of…”
Get full text

Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study by Castagneto, Bruno, Zai, Silvia, Dongiovanni, Diego, Muzio, Alberto, Bretti, Sergio, Numico, Gianmauro, Botta, Mario, Sinaccio, G

“…Aims of this study were to evaluate the activity and toxicity of gemcitabine and cisplatin combination in malignant pleural mesothelioma (MPM). Patients with…”
Get full text